Solid organ transplant recipients exhibit more TET2-mutant clonal hematopoiesis of indeterminate potential not driven by increased transplantation risk
CONCLUSIONS: These results demonstrate that recipients of solid organ transplants display a unique pattern of clonal hematopoiesis with enrichment of TET2 driver mutations, the causes of which remain unclear and are deserving of further study.PMID:38551504 | DOI:10.1158/1078-0432.CCR-23-3840 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Alexander J Silver Caitlyn Vlasschaert Taralynn Mack Brian Sharber Yaomin Xu Alexander G Bick C Wright Pinson Michael R Savona Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
Solid organ transplant recipients exhibit more TET2-mutant clonal hematopoiesis of indeterminate potential not driven by increased transplantation risk
CONCLUSIONS: These results demonstrate that recipients of solid organ transplants display a unique pattern of clonal hematopoiesis with enrichment of TET2 driver mutations, the causes of which remain unclear and are deserving of further study.PMID:38551504 | DOI:10.1158/1078-0432.CCR-23-3840 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Alexander J Silver Caitlyn Vlasschaert Taralynn Mack Brian Sharber Yaomin Xu Alexander G Bick C Wright Pinson Michael R Savona Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
Solid organ transplant recipients exhibit more TET2-mutant clonal hematopoiesis of indeterminate potential not driven by increased transplantation risk
CONCLUSIONS: These results demonstrate that recipients of solid organ transplants display a unique pattern of clonal hematopoiesis with enrichment of TET2 driver mutations, the causes of which remain unclear and are deserving of further study.PMID:38551504 | DOI:10.1158/1078-0432.CCR-23-3840 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Alexander J Silver Caitlyn Vlasschaert Taralynn Mack Brian Sharber Yaomin Xu Alexander G Bick C Wright Pinson Michael R Savona Source Type: research
Safety, efficacy, and biological data of T cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial
CONCLUSIONS: TILT-123 was safe and able to produce anti-tumor effects in local and distant lesions in heavily pre-treated patients. Good tolerability of TILT-123 facilitates combination studies, several of which are ongoing (NCT04217473, NCT05271318, NCT05222932, NCT06125197).PMID:38546220 | DOI:10.1158/1078-0432.CCR-23-3874 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 28, 2024 Category: Cancer & Oncology Authors: Santeri A Pakola Katriina J Peltola James H A Clubb Elise Jirovec Lyna Haybout Tatiana V Kudling Tuomo Alanko Riitta Korpisaari Susanna Juteau Marjut Jaakkola Jorma Sormunen Jukka Kemppainen Annabrita Hemmes Teijo Pellinen Mirte van der Heijden Dafne C A Source Type: research
Safety, efficacy, and biological data of T cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial
CONCLUSIONS: TILT-123 was safe and able to produce anti-tumor effects in local and distant lesions in heavily pre-treated patients. Good tolerability of TILT-123 facilitates combination studies, several of which are ongoing (NCT04217473, NCT05271318, NCT05222932, NCT06125197).PMID:38546220 | DOI:10.1158/1078-0432.CCR-23-3874 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 28, 2024 Category: Cancer & Oncology Authors: Santeri A Pakola Katriina J Peltola James H A Clubb Elise Jirovec Lyna Haybout Tatiana V Kudling Tuomo Alanko Riitta Korpisaari Susanna Juteau Marjut Jaakkola Jorma Sormunen Jukka Kemppainen Annabrita Hemmes Teijo Pellinen Mirte van der Heijden Dafne C A Source Type: research
Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers
CONCLUSIONS: sWGS and targeted sequencing identified therapeutic opportunities in 75% of p53abn EC patients. Further research is needed to determine the efficacy of treatments targeting these identified pathways within p53abn ECs.PMID:38536067 | DOI:10.1158/1078-0432.CCR-23-3689 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 27, 2024 Category: Cancer & Oncology Authors: Amy Jamieson Juliana Sobral de Barros Dawn R Cochrane J Maxwell Douglas Sameer Shankar Branden J Lynch Samuel Leung Spencer Martin Janine Senz Amy Lum Yvette Drew C Blake Gilks David G Huntsman Jessica N McAlpine Source Type: research
Best Overall Response-associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
CONCLUSIONS: The refined REDSARC signature provides a potential tool to direct the application of doxorubicin in sarcomas and other malignancies. Validation and further refinement of the signature in other potentially subtype specific prospective cohorts is recommended.PMID:38536068 | DOI:10.1158/1078-0432.CCR-23-3936 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 27, 2024 Category: Cancer & Oncology Authors: Jiangang Liu David S Moura Robin L Jones Amit Aggarwal Ebert J Philip Andrew J Wagner Jennifer Wright Javier Mart ín-Broto William D Tap Source Type: research
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer
CONCLUSIONS: This is the first prospective trial combining an AR antagonist and a non-steroidal selective GR modulator. The combination was safe and well tolerated with PSA response and prolonged disease control observed in a limited subset of patients. Further prospective trials are justified to evaluate efficacy and identify predictive biomarkers of response.PMID:38536082 | DOI:10.1158/1078-0432.CCR-23-3636 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 27, 2024 Category: Cancer & Oncology Authors: Kunal B Desai Anthony V Serritella Walter M Stadler Peter H O'Donnell Randy F Sweis Russell Z Szmulewitz Source Type: research
Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers
CONCLUSIONS: sWGS and targeted sequencing identified therapeutic opportunities in 75% of p53abn EC patients. Further research is needed to determine the efficacy of treatments targeting these identified pathways within p53abn ECs.PMID:38536067 | DOI:10.1158/1078-0432.CCR-23-3689 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 27, 2024 Category: Cancer & Oncology Authors: Amy Jamieson Juliana Sobral de Barros Dawn R Cochrane J Maxwell Douglas Sameer Shankar Branden J Lynch Samuel Leung Spencer Martin Janine Senz Amy Lum Yvette Drew C Blake Gilks David G Huntsman Jessica N McAlpine Source Type: research
Best Overall Response-associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE
CONCLUSIONS: The refined REDSARC signature provides a potential tool to direct the application of doxorubicin in sarcomas and other malignancies. Validation and further refinement of the signature in other potentially subtype specific prospective cohorts is recommended.PMID:38536068 | DOI:10.1158/1078-0432.CCR-23-3936 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 27, 2024 Category: Cancer & Oncology Authors: Jiangang Liu David S Moura Robin L Jones Amit Aggarwal Ebert J Philip Andrew J Wagner Jennifer Wright Javier Mart ín-Broto William D Tap Source Type: research
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer
CONCLUSIONS: This is the first prospective trial combining an AR antagonist and a non-steroidal selective GR modulator. The combination was safe and well tolerated with PSA response and prolonged disease control observed in a limited subset of patients. Further prospective trials are justified to evaluate efficacy and identify predictive biomarkers of response.PMID:38536082 | DOI:10.1158/1078-0432.CCR-23-3636 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 27, 2024 Category: Cancer & Oncology Authors: Kunal B Desai Anthony V Serritella Walter M Stadler Peter H O'Donnell Randy F Sweis Russell Z Szmulewitz Source Type: research
A Phase 0/1 Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas
CONCLUSION: Based on safety, brain tumoral PK, and mechanistic data, 15 mg daily is identified as the RP2D for future trials.PMID:38530160 | DOI:10.1158/1078-0432.CCR-23-3341 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 26, 2024 Category: Cancer & Oncology Authors: Pankaj B Desai Aniruddha Karve Misam Zawit Priyanka Arora Nimita Dave Joy Awosika Ningjing Li Bethany Fuhrman Mario Medvedovic Larry Sallans Ady Kendler Biplab DasGupta David Plas Richard Curry Mario Zuccarello Rekha Chaudhary Soma Sengupta Trisha M Wise- Source Type: research
Unlocking the Pancreatic Cancer Puzzle: Using Intermediate Cells to Target Treatment
Clin Cancer Res. 2024 Mar 26. doi: 10.1158/1078-0432.CCR-23-3295. Online ahead of print.ABSTRACTKRT17-high intermediate cell population with elevated CXCL8 expression informed elevated myeloid infiltration status in tumors and associated with pro-tumorigenic signatures in peripheral granulocytes from pancreatic cancer patients. Further, CXCL8 plasma levels were found to resemble KRT17+/CXCL8+ abundance in tumors, in which higher levels predicted worse patient outcomes.PMID:38530840 | DOI:10.1158/1078-0432.CCR-23-3295 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 26, 2024 Category: Cancer & Oncology Authors: Erika Y Faraoni Florencia McAllister Source Type: research
